P/E ratio for Gilead Sciences (GILD)
P/E ratio as of June 2025 (TTM): 22.6
According to Gilead Sciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 22.5941. At the end of 2024 the company had a P/E ratio of 243.
P/E ratio history for Gilead Sciences from 2001 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | 243 | 1265.27% |
| 2023 | 17.8 | -23.89% |
| 2022 | 23.4 | 59.47% |
| 2021 | 14.7 | -97.48% |
| 2020 | 583 | 3701.51% |
| 2019 | 15.3 | 2.96% |
| 2018 | 14.9 | -26.45% |
| 2017 | 20.2 | 184.87% |
| 2016 | 7.10 | -13.23% |
| 2015 | 8.19 | -30.86% |
| 2014 | 11.8 | -68.31% |
| 2013 | 37.4 | 73.46% |
| 2012 | 21.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | 26.2 | 16.01% | 🇺🇸 USA |
 Vertex Pharmaceuticals VRTX | -118 | -622.26% | 🇺🇸 USA |
 AbbVie ABBV | 78.7 | 248.23% | 🇺🇸 USA |
 Illumina ILMN | -14.9 | -166.03% | 🇺🇸 USA |
 Biogen BIIB | 12.5 | -44.88% | 🇺🇸 USA |
 Pfizer PFE | 17.2 | -23.96% | 🇺🇸 USA |
 Johnson & Johnson JNJ | 16.6 | -26.43% | 🇺🇸 USA |
 Eli Lilly LLY | 63.5 | 181.20% | 🇺🇸 USA |
 Merck MRK | 11.5 | -49.12% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.